bioMérieux – Business review for the nine months ended September 30, 201718 October, 2017
- Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation
- €1,674 million in sales
- Up 10.8% as reported
- In microbiology, growth accelerated to nearly 8%
- Contribution from all regions to the Group's strong sales dynamic, particularly the Asia-Pacific region, with sales in China and India up almost 15%
Alexandre Mérieux, Chief Executive Officer, said: "Third-quarter growth for bioMérieux once again reflected the strong sales dynamic we have enjoyed for several quarters. Robust growth for the microbiology lines and sustained growth for the molecular biology lines pushed sales up by more than 10% for the first nine months of the year, placing us firmly on track to achieving our annual targets."
Marcy l'Étoile, October 18, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2017.